论文部分内容阅读
目的探讨C-kit受体(CD117)和血小板衍生生长因子受体-α(platelet-derived growth factor receptor-α,PDGFR-α)在骨肉瘤发病中的作用及其与骨肉瘤临床病理分型及预后的关系。方法采用免疫组化EnVision两步法检测60例骨肉瘤和10例骨瘤(对照组)中CD117和PDGFR-α的表达,分析二者的表达与骨肉瘤病理分型及临床预后的关系。结果骨肉瘤中CD117阳性率为66.7%(40/60),显著高于对照组(P<0.05);PDGFR-α阳性率为61.7%(37/60),显著高于对照组(P<0.05)。骨肉瘤中CD117和PDGFR-α表达无相关性(P>0.05)。CD117和PDGFR-α表达与病理分型无显著关系,与临床分期及预后密切相关。结论骨肉瘤中CD117及PDGFR-α的表达与其生物学行为密切相关,对评价患者的预后及指导临床治疗具有一定的参考价值。
Objective To investigate the role of C-kit receptor (CD117) and platelet-derived growth factor receptor-α (PDGFR-α) in the pathogenesis of osteosarcoma and its clinical significance. Prognosis of the relationship. Methods The expressions of CD117 and PDGFR-α in 60 osteosarcomas and 10 osteosarcomas (control group) were detected by immunohistochemical EnVision two-step method. The relationship between the expression of CD117 and PDGFR-α and the pathological type and clinical prognosis of osteosarcoma were analyzed. Results The positive rate of CD117 in osteosarcoma was 66.7% (40/60), which was significantly higher than that in control group (P <0.05). The positive rate of PDGFR-α was 61.7% (37/60) ). There was no correlation between the expression of CD117 and PDGFR-α in osteosarcoma (P> 0.05). The expression of CD117 and PDGFR-α had no significant relationship with pathological type, which was closely related to clinical stage and prognosis. Conclusion The expression of CD117 and PDGFR-α in osteosarcoma is closely related to the biological behavior of osteosarcoma, which is of certain reference value for evaluating the prognosis of patients and guiding the clinical treatment.